Pegcetacoplan

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 289 publications

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Journal: Hematology (Amsterdam, Netherlands)

Published: June 11, 2026

Short-Term Intraocular Pressure Trends After Intravitreal Pegcetacoplan Injection.

Short-Term Intraocular Pressure Trends After Intravitreal Pegcetacoplan Injection.

Journal: Journal of vitreoretinal diseases

Published: May 26, 2026

Complement Inhibition in Geographic Atrophy: Clinical Evidence for Pegcetacoplan and Avacincaptad Pegol.

Complement Inhibition in Geographic Atrophy: Clinical Evidence for Pegcetacoplan and Avacincaptad Pegol.

Journal: Cureus

Published: May 19, 2026

Geographic atrophy: From slowing lesions to preserving vision.

Geographic atrophy: From slowing lesions to preserving vision.

Journal: Current opinion in ophthalmology

Published: May 09, 2026

Efficacy and Safety of the C3 Inhibitor Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.

Efficacy and Safety of the C3 Inhibitor Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.

Journal: European journal of haematology

Published: May 04, 2026

Real-World Case Series of Intravitreal Pegcetacoplan for Geographic Atrophy Secondary to Age-related Macular Degeneration in Switzerland.

Real-World Case Series of Intravitreal Pegcetacoplan for Geographic Atrophy Secondary to Age-related Macular Degeneration in Switzerland.

Journal: Klinische Monatsblatter fur Augenheilkunde

Published: April 20, 2026

Real-world Safety Profile of Avacincaptad Pegol in the Management of Geographic Atrophy.

Real-world Safety Profile of Avacincaptad Pegol in the Management of Geographic Atrophy.

Journal: Ophthalmic surgery, lasers & imaging retina

Published: March 27, 2026

Efficacy and Safety of Treatments for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review.

Efficacy and Safety of Treatments for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review.

Journal: Journal of clinical medicine

Published: March 26, 2026

Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment.

Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment.

Journal: Journal of comparative effectiveness research

Published: March 19, 2026

Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.

Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.

Journal: The New England journal of medicine

Published: March 11, 2026

Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. Reply.

Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. Reply.

Journal: The New England journal of medicine

Published: March 11, 2026

Pegcetacoplan Delivers Real-World Therapeutic Benefits and Reduces Disease Burden for Patients With Paroxysmal Nocturnal Haemoglobinuria: A Systematic Literature Review of Pegcetacoplan Real-World Clinical and Patient-Reported Outcomes.

Pegcetacoplan Delivers Real-World Therapeutic Benefits and Reduces Disease Burden for Patients With Paroxysmal Nocturnal Haemoglobinuria: A Systematic Literature Review of Pegcetacoplan Real-World Clinical and Patient-Reported Outcomes.

Journal: European journal of haematology

Published: February 26, 2026

Showing 1-12 of 289

Last Updated: 06/30/2026